First patient receives ImmunityBio’s second-generation hAd5 COVID vaccine, delivering both outer S (spike) protein and inner N (nucleocapsid) leading to potential long-term T cell and antibody immunity to the SARS-CoV-2 virus CULVER CITY, Calif. & EL SEGUNDO, Calif. --(BUSINESS WIRE)--Oct.
First human adenovirus (hAd5) vector vaccine candidate to deliver both outer spike (S) and inner nucleocapsid (N) antigens from SARS-CoV-2, offering potential long-term T cell and antibody immunity to the SARS-CoV-2 virus Second-generation adenoviral vector platform designed to generate immune
Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer.
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Sep. 21, 2020-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong , M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6,
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product EL SEGUNDO, Calif. & CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 24, 2020-- NantKwest, Inc.
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory. Inclusion of nucleocapsid in this vaccine construct potentially
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 29, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock
